cas 59074-26-9|| where to buy 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole

Product Name:3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole

IUPAC Name:3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole

Packing Unit	Available Stock	Price($)
CM126738-1g	in stock	ƚƚ
CM126738-5g	in stock	ǠȤœ
CM126738-25g	1-2 Weeks	Ÿşƴ
CM126738-100g	1-2 Weeks	ǠȋƚȤ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 59074-26-9 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:59074-26-9; Molecular Formula:C15H13ClN2; Melting Point:-; Smiles Code:ClC1=CC=C(C2=NNCC2C3=CC=CC=C3)C=C1; Density:

: Catalog Number:CM126738; Molecular Weight:256.73; Boiling Point:393°C at 760 mmHg; MDL No:MFCD07776855; Storage:Store at 2-8°C.

: Pyrazolines; Pyrazoline is a heterocyclic chemical compound with the molecular formula C3H6N2. Pyrazolines are well-known and important nitrogen-containing five-membered ring heterocyclic compounds. Pyrazoline derivatives have numerous prominent pharmacological effects, such as antimicrobial, anti-inflammatory, analgesic, antidepressant and anticancer.

: Pyrazoles; Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.

: Monlunabant; Obesity is linked to overactivity of the endocannabinoid system that regulates appetite, fat storage, and insulin resistance. Cannabinoid receptor type-1 (CB1) belongs to the G protein-coupled receptor (GPCR) superfamily, and are found in the brain and peripheral tissues. Pharmacological blockers of CB1 receptors have demonstrated effectiveness in suppressing appetite, inducing weight loss, enhancing energy expenditure and speeding up metabolism.
Novo Nordisk’s Monlunabant is a novel peripherally-acting CB1 receptor blocker. This target limits brain penetration and minimizes psychiatric side-effects. Monlunabant is developed for the treatment of metabolic disorders. The phase 2 trials for diabetic kidney disease and obesity is expected in the second half of 2024.